Skip to main content
. 2014 May 6;16(3):235–246.e1. doi: 10.1016/j.neo.2014.03.005

Figure 5.

Figure 5

Sunitinib treatment significantly reduces MMP activity in HaCaT-rasA-5RT3 tumors. (A) Assessment of MMP activity in vivo by FMT/μCT hybrid imaging demonstrates significantly decreased concentrations of activated MMPSense 750 FAST in sunitinib-treated tumors (***P < .001; n = 5) compared with untreated controls (n = 4). (B) Quantification of in situ zymography of MMP activity on tumor sections confirms again the in vivo results. (C) Representative FMT/μCT fusion images of tumor-bearing mice (transverse plane) show the fluorescent signals of activated MMPSense 750 FAST in an untreated control and sunitinib-treated tumor (tumors indicated by a white arrow). (D) Representative images of in situ zymography of MMP activity (green) counterstained with collagen IV (red) and DAPI (blue) of an untreated control and sunitinib-treated tumor. (E) Representative H&E staining of the different HaCaT-ras A-5RT3 tumors. Bar, 200 μm. Data are presented as means ± SD (**P < .01 and ***P < .001).